Gege Gui retweeted
Great talks today at #iwAL26 in Cambridge, MA from Drs @GegeGui0 and Sushree Sahoo. fbri.vtc.vt.edu/people-direc… @vt_dcarea @FralinBiomed
Gege Gui retweeted
Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at #ASH25 #ASH2025 - the largest cohort of paired tumor and remission WGS from patients with AML meetings-api.hematology.org/…
Gege Gui retweeted
So proud of our HouriganLab #ASH23 superstar abstract award winners - biostats PhD student @GegeGui0 (oral on IDH2 MRD tomorrow Sun in sess617 at 9.30am and poster on IDH1 MRD on Mon) and medical student @hegdepranay1 presenting TKD MRD poster tomorrow (Sun).
Gege Gui retweeted
She crushed it! First major international talk for @GegeGui0 - biostatistics PhD student and key member of staff in Hourigan lab. The first, but not the last, time for her talking at ASH. @TheBethesdaLabs @CIBMTR @ASH_hematology
Gege Gui retweeted
Cleveland clinic medical student @ClevelandClinic @hegdepranay1 presenting work he did on FLT3-TKD MRD during a MRSP year in our lab at @TheBethesdaLabs @NIH @CIBMTR
Gege Gui retweeted
Excited to finally share our work published today in JAMA! jamanetwork.com/journals/jam…
Gege Gui retweeted
DNA Sequencing to Detect Residual Disease for Acute Myeloid Leukemia ja.ma/3JgqIBj via @JAMA_current part of @JAMANetwork
Gege Gui retweeted
Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission medrxiv.org/content/10.1101/…
Gege Gui retweeted
During #ASCO2022 , the AML Hub spoke with @DrChrisHourigan, @NIH. We asked, Can pre-transplant MRD testing predict patients who are more likely to relapse?
👉 loom.ly/DC-0-Fk 👈
#AML #AMLsm #leusm #leukemia
Gege Gui retweeted
AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation | ASH Clinical News | American Society of Hematology ashpublications.org/ashclini…
Gege Gui retweeted
MRD in AML was previously most useful for papers, not patients. Until now! @DrChrisHourigan moving us into the “getting stuff done era” with this Herculean 1075 pt study of MRD in CR1 heading to SCT. #ASCO #leusm
Gege Gui retweeted
Excited for @DrChrisHourigan to present our latest results tomorrow at 11:45AM CT from the Pre-MEASURE study at #ASCO2022 examining #MRD in a large cohort of #AML patients prior to transplant. Stick around for the last session! #savingthebest4last https://teapawt.net/t.co/LKY6ITj7gS
Gege Gui retweeted
CONGRESS #ASCO22 | @DrChrisHourigan @NIH discusses MRD testing prior to allo-SCT for pts with AML in first remission in the Pre-MEASURE study. (N=457). NGS-MRD prior to alloHCT in AML CR1 was prognostic. #leusm #leukemia
Gege Gui retweeted
From the July issue: Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid #Leukemia from Nonmalignant #ClonalHematopoiesis. #leusm #singlecell @nih_nhlbi @LauraWDillon @DrChrisHourigan
https://teapawt.net/t.co/lIvVXZjpeJ
Excited to share our work @Meg_Goswami Grateful for all the support from co-authors and especially our brilliant and caring mentor @DrChrisHourigan
Replying to @DrChrisHourigan
I’m so proud of @Meg_Goswami and @GegeGui0 for this work. While this was only a small clinical trial they have shown with their strong logic and beautiful science that in AML patients there was no evidence that adding anti-PD1 treatment to HMA resulted in additional benefit.
7
Gege Gui retweeted
Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis bloodcancerdiscov.aacrjourna…
New preprint from houriganlab.com @TheBethesdaLabs We are obsessed with MEASURABLE residual disease in AML, the idea that with higher sensitivity tools we can get better sense of leukemic burden and relapse risk for individuals in “remission”.
Gege Gui retweeted
Summary of pre-alloHCT NGS testing in MDS and AML cohorts of @BMTCTN 0901 clinical trial from @TheBethesdaLabs @GegeGui0 @LauraWDillon Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. ascopubs.org/doi/abs/10.1200…
Gege Gui retweeted
Spending weekend preparing my talk for big pre-tenure external review. Reflecting how proud I am of amazing work my team at houriganlab.com has done over past four years despite Covid19. Fifty publications. Two plenary + 40 other talks. 8 awards. Great post-lab jobs.
Gege Gui retweeted
New results from the @BMT_CTN 0901 trial and @TheBethesdaLabs @nih_nhlbi: The Impact Of Conditioning Intensity And Genomics On Relapse After Allogeneic Transplantation For Patients W/ Myelodysplastic Syndrome fal.cn/3dAoo #jcopo

























